For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Methotrexate - Inflammatory bowel disease
PAD Profile : Methotrexate - Inflammatory bowel disease Important
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Adalimumab
- Azathioprine
- Infliximab
- Mercaptopurine
- Ciclosporin
- Golimumab
- Vedolizumab
- Allopurinol
- Balsalazide sodium
- Prednisolone
- Budesonide
- Tofacitinib
- Mesalazine (Systemic)
- Filgotinib
- Sulfasalazine
- Upadacitinib
- Risankizumab
- Olsalazine sodium
Other Indications
- Psoriatic arthritis
- Dermatology indications
- Neurology indications
- Uveitis
- Respiratory disease indications
- Rheumatology indications
- Scleritis
Additional Documents
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed a local adaptation of the National Shared Care document, in reference to the routine monitoring of CRP (rather than ESR) in primary care for inflammatory indications
The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approve the RMOC national shared care protocol with ‘local adaptations’.
This shared care protocol applies to adults aged 18 and over.
This shared care protocol also includes treatment of chronic inflammatory conditions where off-label use of methotrexate is appropriate, including, but not limited to, the specialities and conditions described in Section 3 of the document.
These indications are off-label. The specialist must specify the indication for each patient when initiating shared care and clearly state when use is off-label (refer to section 3 for further information).